Skip to Content
Merck
  • A retrospective assessment of the incidence of respiratory depression after neuraxial morphine administration for postcesarean delivery analgesia.

A retrospective assessment of the incidence of respiratory depression after neuraxial morphine administration for postcesarean delivery analgesia.

Anesthesia and analgesia (2013-11-22)
Theresa R Crowgey, Jennifer E Dominguez, Cathleen Peterson-Layne, Terrence K Allen, Holly A Muir, Ashraf S Habib
ABSTRACT

Respiratory depression can occur after neuraxial morphine administration. In the obstetric population, there are little data on respiratory depression after neuraxial morphine administration in women undergoing cesarean delivery. In this single-center, retrospective study in 5036 obstetric patients (mean body mass index = 34 kg/m) who underwent cesarean delivery and received neuraxial morphine, we did not identify any instances of respiratory depression requiring naloxone administration or rapid response team involvement. Therefore, the upper 95% confidence limit for respiratory depression in our study is 0.07% (1 event per 1429 cases).

MATERIALS
Product Number
Brand
Product Description

Supelco
Morphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Morphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Morphine sulfate salt pentahydrate
Supelco
Morphine sulfate salt solution, 1.0 mg/mL in methanol, drug standard